Clinical Trial Update: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating frontline tislelizumab in patients with de novo Hodgkin lymphoma who are unsuitable for standard…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Hodgkin Lymphoma | Phase 2 | Status: RECRUITING